Acarix announced today that the company has appointed Ms. Helen Ljungdahl Round as head of the company’s newly established US subsidiary Acarix Inc. Helen will assume her position in September 2021 and build the US organization. She will be a […]
Tag: Acarix
New health economic study proves the value of CADScor® in coronary disease diagnostics
A peer-reviewed publication in the September 2021 edition of PharmacoEconomics shows an estimated 12.3£ million savings to the English health care system per 100,000 eligible patients when using the Acarix CADScor system to rule out coronary artery disease (CAD). Coronary […]
Preliminary Dan-NICAD II results to be presented at ESC
Malmö, Sweden, August 23, 2021 Preliminary Dan-NICAD II results to be presented at ESC Acarix AB (publ) today announced that the preliminary results of the Dan-NICAD II study will be presented at the ESC congress on 27AUG2021. The Dan-NICAD II trial was initiated in January 2018 to […]
Positive preliminary data from Acarix’s exploratory heart failure study SEISMO
Press release Malmö, Sweden, January 13, 2021 Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application. […]
Acarix announces the last patient included in Dan-NICAD II study
Press release Malmö, Sweden December 9, 2020 Acarix announces the last patient included in Dan-NICAD II study After the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of non-invasive diagnostic […]
FDA identifies exclusive code for the CADScor®
Press release (MAR) Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and further analysis of the FDA approval, Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US […]
Acarix receives US market approval for the CADScor® System
Press release (MAR) Malmö, Sweden November 25, 2020 Acarix receives US market approval for the CADScor® System Acarix AB (publ) today announced that the US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of […]
Acarix announce final outcome in oversubscribed rights issue
Press release Malmö, Sweden September 11, 2020 Acarix announce final outcome in oversubscribed rights issue Acarix AB (“Acarix” or the “Company”) has completed the new share issue of a maximum of 86,156,738 shares with preferential rights for the Company’s existing […]
Acarix publishes a supplement to the prospectus
Press release Malmö, Sweden September 3, 2020 Acarix publishes a supplement to the prospectus The board of directors of Acarix AB (“Acarix” or the “Company”) has prepared a supplement to the prospectus regarding invitation to acquire shares in the approved […]
Acarix two largest shareholders transfer subscription rights free of charge – extends the subscription period
Press release Malmö, September 2, 2020 Acarix two largest shareholders transfer subscription rights free of charge –extends the subscription period The Extraordinary General Meeting of Acarix AB (“Acarix” or the “Company”) resolved on 11 August 2020, subsequent to the […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet